Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
JPY 25730.00
JPY 14940.00
JPY 28220.00
JPY 53120.00
JPY 94620.00

カスタマーフィードバック(3)

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MmSySpVv[3Srb36gRZN{[Xl? MVuwMlXDqM7:TR?= MXiyOEBp MmrVe4F1\XJ? NUCwcWhWdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? MojQNlUyOjNyOEK=
Eca109 NHG0[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHIUJlzOC53L{KuOU82KM7:TR?= Ml;0NlQwPDhxN{KgbC=> M4D3VpdifGW{ NIH4fIVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NFr3U3ozPTF{M{C4Ni=>
Eca109 NHG3S2pHfW6ldHnvckBCe3OjeR?= NX;zd4lROC53wrFOwG0> MVu2M|EzNzJ2IHi= NVfuenVKf2G2ZYK= MnvabY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= M3HoRlI2OTJ|MEiy
Eca109 MVzGeY5kfGmxbjDBd5NigQ>? NFq1SHQxNjYEoN88US=> M4KwbFI1KGh? M4DqV5difGW{ M3KzXIlvcGmkaYTzJINmdGxiaX72ZZNqd25? NULuTXo4OjVzMkOwPFI>
Eca109 M3rkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH2fWExNjYEoN88US=> M3ryRlI1KGh? NF;ZcnJ4[XSnch?= NXHmdopMcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? M{LoUlI2OTJ|MEiy
Eca109 MoL2SpVv[3Srb36gRZN{[Xl? NVflenI1OC53L{Gg{txO NXOwSGRrOjRiaB?= MlLhe4F1\XJ? M2fNTYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MknsNlUyOjNyOEK=
SW1116  NEe4eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzQOFgxNjVxMT:yM|Uh|ryP NU[3b3JrPDhiaB?= M2foZmROW09? NFT2SoRmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v NV\v[I5OOjR6N{SyPFY>
LOVO M3LIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnVWFIxNjVxMT:yM|Uh|ryP MXu0PEBp M3j0OmROW09? Mkm3[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NF7pWFIzPDh5NEK4Oi=>
SW1116  MYrGeY5kfGmxbjDBd5NigQ>? NWPGR2tFOTBizszN MX20PEBp NHvSNWRFVVOR NGLZSY1qdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? MmHHNlQ5PzR{OE[=
LOVO NHLyWJNHfW6ldHnvckBCe3OjeR?= NHjyTFMyOCEQvF2= NEXSO5M1QCCq M1zuNWROW09? NUfqWXBlcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MWiyOFg4PDJ6Nh?=
SW1116  NEPCRWZCeG:ydH;zbZMhSXO|YYm= M3HJ[lExKM7:TR?= MVi0PEBp NHzy[HlFVVOR M1nxdYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NGLTWnczPDh5NEK4Oi=>
LOVO MYXBdI9xfG:|aYOgRZN{[Xl? NF\BNZcyOCEQvF2= MUi0PEBp M2HLWGROW09? NEnPS5dmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> M4f4RlI1QDd2Mki2
RPMI-8226 M4TVdWFxd3C2b4Ppd{BCe3OjeR?= MYWxM|Ih|ryP NWG0NFZ7PDhxN{KvPVYhcA>? MkXUSG1UVw>? NHPUeGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{\vfVI1QDN|MUC4
OPM-2  NYrje2prSXCxcITvd4l{KEG|c3H5 MVexM|Ih|ryP M2jlUlczNzl4L{GyNEBp M3G2UmROW09? MXzpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{XCOVI1QDN|MUC4
JJN3  M1\iTGFxd3C2b4Ppd{BCe3OjeR?= MV6wMlUwOSEQvF2= NFS3[ZMzPC92ODDo M{n3eWROW09? MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mm\2NlQ5OzNzMEi=
NCI-H929  M4L2bGFxd3C2b4Ppd{BCe3OjeR?= M4PaVFEwOiEQvF2= NX\jcmhSPzJxOU[vNVIxKGh? M4jYVWROW09? M1XXW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVXzUop{OjR6M{OxNFg>
RPMI-8226 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrvNU8zKM7:TR?= NH:zdm0zPC92OD:3NkBp M{T3eGROW09? Ml\NZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? M1zIe|I1QDN|MUC4
OPM-2  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCwSYNxOS9{IN88US=> MoC4NlQwPDhxN{KgbC=> NVz2bolFTE2VTx?= MmXnZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MojhNlQ5OzNzMEi=
JJN3  M2LJZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHQNE42NzFizszN MUKyOE81QC95MjDo NITpNItFVVOR NHXQRoVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NHTI[YgzPDh|M{GwPC=>
NCI-H929  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxM|Ih|ryP MV:yOE81QC95MjDo MU\EUXNQ MVPh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? Mmm2NlQ5OzNzMEi=
HeLa Mnf6T4lv[XOnIFHzd4F6 M1H1OmtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> M1fjblI1PzhyMEm4
HeLa NGfwOWtMcW6jc3WgRZN{[Xl? MYLLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= M1PLOlI1PzhyMEm4
HeLa NFHhcHBMcW6jc3WgRZN{[Xl? NVOwS5RiU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? MV:yOFc5ODB7OB?=
HeLa MXTLbY5ie2ViQYPzZZk> M{TnTGtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> MlqxNlQ4QDByOUi=
NB4 MnLRSpVv[3Srb36gRZN{[Xl? NUG0cVF6Oi53L{WvO{42NzFyIN88US=> NYOy[5R7OjRiaB?= NEPpU4ZFVVOR M{fTcYlv[3KnYYPlZUB1cGViZYjwdoV{e2mxbjDv[kBxemWldYLzc5IhdWmULUGyOYE> NV3GSWgyOjR2OES4O|A>
CD4+ CD25− T  NUDqPZgyTnWwY4Tpc44hSXO|YYm= M2m3cFEwPSEQvF2= M4DoUpJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NXTHcm46OjR2N{[zOlA>
BV-173 M1fzVGFxd3C2b4Ppd{BCe3OjeR?= MkXYNE4zPS9yLkWvNE44PS9zIN88US=> NVHWOIZNPDhxN{KvPVYhcA>? MnHjxsBRSlN? M4PjV4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWnmbnhXOjR2MkO2NVM>
ML-1 NEnPSmNCeG:ydH;zbZMhSXO|YYm= NXXZPGNIOC5{NT:wMlUwOC55NT:xJO69VQ>? M2rKPVQ5Nzd{L{m2JIg> NXuwVI5pyqCSQmO= NEn0VYVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MVGyOFQzOzZzMx?=
HL-60 NX\1bmg4SXCxcITvd4l{KEG|c3H5 NFv4WXAxNjJ3L{CuOU8xNjd3L{Gg{txO NUnkU3hpPDhxN{KvPVYhcA>? MnzrxsBRSlN? MleybY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MX:yOFQzOzZzMx?=
KG-1a NVPOZnloSXCxcITvd4l{KEG|c3H5 NWfHVmNiOC5{NT:wMlUwOC55NT:xJO69VQ>? NGjGelY1QC95Mj:5OkBp NWD1UVA1yqCSQmO= NYfaVJFMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MVOyOFQzOzZzMx?=
BV-173 NVPab2lRTnWwY4Tpc44hSXO|YYm= MnLwNlUxNzVyMH7N MnrLOFghcA>? MYlCpHBDWw>? M4r5dolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NFfjXHEzPDR{M{[xNy=>
CEM MojiSpVv[3Srb36gRZN{[Xl? M4PKTFI2OC93MEDuUS=> MnLIOFghcA>? M33Tc:KhWEKV Mm\nbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn NW[1[XlROjR2MkO2NVM>
HL-60 MoS0SpVv[3Srb36gRZN{[Xl? MWmyOVAwPTBybl2= NX7vRYZ2PDhiaB?= MWNCpHBDWw>? NH;Qd|BqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NWHzd2x4OjR2MkO2NVM>
ML-1 NIe2cFRHfW6ldHnvckBCe3OjeR?= MXGyOVAwPTBybl2= MUe0PEBp MX5CpHBDWw>? NUDqU3hOcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MUmyOFQzOzZzMx?=
DLD-1 MX\GeY5kfGmxbjDBd5NigQ>? NEn6cY4zPTBxNUCwcm0> NX\zb|Q1PDhiaB?= MVtCpHBDWw>? M4TyfoRwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M1jER|I1PDJ|NkGz
HCT-116 NY\BNodHTnWwY4Tpc44hSXO|YYm= Mk[3NlUxNzVyMH7N MWm0PEBp NFjxZ5bDqFCEUx?= NG\0TJdldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M3zGPVI1PDJ|NkGz
U937-A/E-9/14/18  NHTqWFhCeG:ydH;zbZMhSXO|YYm= M1rofVAvODFxMD6xM|EwOTBizszN MVW0PEBp MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NWH4R5pPOjR|MEC0OVY>
HT29 NGHsZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPKdXMzPzJiaB?= M2rUVGlEPTB;MUSwNOKyOTd7IN88US=> NELVVm0zPDF5MkC2NS=>
SW48 NV3XdJNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fqWlczKGh? MluzTWM2OD1zNT6yxtE3NjJizszN MUOyOFE4OjB4MR?=
HCT116 M1z3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ZNGM4OiCq MoraTWM2OD1zLkhCtVAvPCEQvF2= NUjPbIhROjRzN{KwOlE>
HepG2 NXHWTHVJTnWwY4Tpc44hSXO|YYm= NEfab5cxNjVxMTFOwG0> NU\R[FlmOjRiaB?= NVLKU4c3TE2VTx?= NUX4WG06fXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NYLVUVh7OjRzNE[4O|Q>
LS174T NVO2V|FMTnWwY4Tpc44hSXO|YYm= MoXjNE42NzFizszN NXPGPWw5OjRiaB?= M{LMU2ROW09? NYPQb2JwdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> M{XZfFI1OTR4OEe0
HepG2 MWjBdI9xfG:|aYOgRZN{[Xl? NEPyRZoyNzFyL{GwNEDPxE1? NGji[GI4KGR? M3qxOGROW09? M33KW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4THeVI1OTR4OEe0
LS174T MmX6RZBweHSxc3nzJGF{e2G7 M3[4[lEwOTBxMUCwJO69VQ>? MkjxO{Bl M3S0cWROW09? NH3JdnNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVuyOFE1Pjh5NB?=
QBC-939 MV\BdI9xfG:|aYOgRZN{[Xl? Mn\QNU8yOC9zMECg{txO MX63JIQ> NVnETlNJTE2VTx?= NV\RSVF6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUiyOFE1Pjh5NB?=
U251 NH\NTJJCeG:ydH;zbZMhSXO|YYm= NVva[pl2OS9zMD:xNFAh|ryP NF:zRXI4KGR? NV7OOm1NTE2VTx?= M3LHN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXmyOFE1Pjh5NB?=
HL-60 NX35PGN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvOUJZVOSEQvF2= M{T6Z|Q5KGh? NUTVWGdPcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= NY\zPINHOjRyMECzNlQ>
MDA‑MB‑453 MnjDSpVv[3Srb36gRZN{[Xl? MoPnNE4zNzFizszN MXK3NkBp NEPHcFRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MkT2NlM5PDR{Mki=
HCC1569 M4DFV2Z2dmO2aX;uJGF{e2G7 NEn1TYoxNjJxMTFOwG0> M4r3c|czKGh? MWDjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MmHpNlM5PDR{Mki=
BT‑474 Ml3VSpVv[3Srb36gRZN{[Xl? MWKwMlIwOSEQvF2= NHTGboo4OiCq Ml;xZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NWnOTmw6OjN6NESyNlg>
AGS NITHPXFCeG:ydH;zbZMhSXO|YYm= NVfIfGhiPS9zMD:yNE82OCEQvF2= Mn\IOFjDqGkEoB?= NFfkU|VFVVOR MlrrbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NVrjbmhSOjN3OEK3PFQ>
A549 MW\BdI9xfG:|aYOgRZN{[Xl? M3TTN|UwOTBxMkCvOVAh|ryP NGGx[JQ1QMLiaNMg NUjvTHh3TE2VTx?= M371folvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NHzBWJYzOzV6Mke4OC=>
AGS  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT4fpU2NzFyL{KwM|UxKM7:TR?= M4fCblQ5yqCqwrC= MkfqSG1UVw>? MWrpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NVS2dFRFOjN3OEK3PFQ>
Kasumi-1 NWTSNolmSXCxcITvd4l{KEG|c3H5 M2jUblAvPSEQvF2= NI\nO4I1QMLiaNMg M4rBV4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NFzaToUzOzR7M{O0PC=>
OCI-AML3 M2rwfGFxd3C2b4Ppd{BCe3OjeR?= NHfG[HIzNjVizszN NXqxUXBqPDkEoHlCpC=> M4rzSoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NW\qSYo{OjN2OUOzOFg>
MV4-11 NX3YUVFVSXCxcITvd4l{KEG|c3H5 NXjrc4xWOi53IN88US=> Mk\jOFjDqGkEoB?= MlPl[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NVHnWG9QOjN2OUOzOFg>
NK  M1:0c2N6fG:2b4jpeJkhSXO|YYm= NHftRZkxNjB{LUKwJO69VQ>? MX:1JIQ> NIPh[Vll\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n MXuyN|MzQDB6OB?=
NK  MkfZRZBweHSxc3nzJGF{e2G7 MnvFNE4xOi1{MDFOwG0> MkHPOUBl Mn;5[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MWCyN|MzQDB6OB?=
NK  MUXGeY5kfGmxbjDBd5NigQ>? MV2wMlAyNTJyIN88US=> NVqyW3B5PSCm M1;xdYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> MkP6NlM{OjhyOEi=
MOLT4/DNR MWTGeY5kfGmxbjDBd5NigQ>? NVP5WnF7PSEQvF2= NImyPVA1KGR? M1jsVZJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NVTJdFF1OjNyNkC1O|A>
Jurkat/DOX MYjGeY5kfGmxbjDBd5NigQ>? M1zVNFUh|ryP M33wNFQh\A>? MnXvdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NITs[mozOzB4MEW3NC=>
MOLT4/DNR NVvZ[G1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi1JO69VQ>? NGL5Nos1KGR? MnPTdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NIiwWZQzOzB4MEW3NC=>
Jurkat/DOX NXnEfW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T6TFUh|ryP NHPKZY81KGR? NV3MNm9CemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MVqyN|A3ODV5MB?=
ccRCC  NYHDOlJVSXCxcITvd4l{KEG|c3H5 MV[wMlAyNTFyzszN M37ibVczKGh? NV3uWY1TTE2VTx?= MoGzbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? M1jGRVIzQDJ4NE[3
TNBC  MXLBdI9xfG:|aYOgRZN{[Xl? M1f2flAvODFvMUFOwG0> M2C4OlczKGh? MkX3SG1UVw>? NWLJZ5NJcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= NHe5NG8zOjh{NkS2Oy=>
A498 NFXrTWpCeG:ydH;zbZMhSXO|YYm= MnnkNE4xOS1zMN88US=> M2OzN|czKGh? M2TBUWROW09? NHn5[XFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MUeyNlgzPjR4Nx?=
KIJ265T MmOwRZBweHSxc3nzJGF{e2G7 MU[wMlAyNTFyzszN NUjTfYV{PzJiaB?= MoTDSG1UVw>? MUHpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu NF\ORlMzOjh{NkS2Oy=>
MDA-231 MmHMRZBweHSxc3nzJGF{e2G7 NF\sT2ExNjBzLUGw{txO NYHXVYZ5PzJiaB?= NXLFb29{TE2VTx?= MkTVbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M3nkU|IzQDJ4NE[3
BT-20 M33rVmFxd3C2b4Ppd{BCe3OjeR?= Mlr2NE4xOS1zMN88US=> MVi3NkBp Mk\rSG1UVw>? M4fzSolv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MlHtNlI5OjZ2Nke=
U937 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMdFUuOjBizszN MXyyOE81QC95MjDo NWixUVRScW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MXiyNlc3PzB{MR?=
HL60 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoruOU0zOCEQvF2= M2TNNFI1NzR6L{eyJIg> NFfSOoVqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NYnRT2pOOjJ5NkewNlE>
U937 M3XSVGFxd3C2b4Ppd{BCe3OjeR?= M{PH[VE2KM7:TR?= MUCyOE81QC95MjDo MU\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGr4c|UzOjd4N{CyNS=>
HL60 MUPBdI9xfG:|aYOgRZN{[Xl? NEnwNY8yPSEQvF2= NIXEN|MzPC92OD:3NkBp M{nuR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml\3NlI4PjdyMkG=
LS411N  MkPyRZBweHSxc3nzJGF{e2G7 M2TRTVAvPSEQvF2= MlHMO|IhcA>? MoC0bY5kemWjc3XzJGZieyCvUl7BJIxmfmWu Mn;WNlI1PjF4OUW=
MDA-MB-231 NIftSItCeG:ydH;zbZMhSXO|YYm= MYmxNEDPxE1? NVnvU2VzPDhiaB?= Ml\LdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYiyNVg5PzZ7Nx?=
MCF-7  MVvBdI9xfG:|aYOgRZN{[Xl? NHXpPIQyOCEQvF2= MkH1OFghcA>? M1f2fZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYnSOXdpOjF6OEe2PVc>
A375 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqwMlUh|ryP NYj6UopVOS93L{ig[C=> M3X3W4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NFHQ[YczOTd7Nk[yNi=>
SKMEL1 M3e5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPKNE42KM7:TR?= MY[xM|UwQCCm M37tU4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M4rCTFIyPzl4NkKy
SKMEL3 MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[wMlUh|ryP MoTUNU82NzhiZB?= MYPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MXyyNVc6PjZ{Mh?=
SKMEL28 NVfvcGUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4izcFAvPSEQvF2= M1G3XVEwPS96IHS= MlT5bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MVWyNVc6PjZ{Mh?=
MeWo NV7qN2xtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHCOnAxNjVizszN NILNV2gyNzVxODDk MkL4bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NGHpWGszOTd7Nk[yNi=>
B16 NH;yR3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Ebng3OC53IN88US=> MkPUNU82NzhiZB?= NIT4Z4FqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MVqyNVc6PjZ{Mh?=
Ly 1 NEPzTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHZdYJLOjRiaB?= MlTaTWM2OD15LkOg{txO NVTFRnh4OjF5N{KwOFk>
Ly 7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[3cpRxOjRiaB?= NWK3O5Q3UUN3ME2xNE44KM7:TR?= MV[yNVc4OjB2OR?=
Su-DHL6 M4\FdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT2NlQhcA>? NYLle48yUUN3MP-8olIxKM7:TR?= M4T0clIyPzd{MES5
Ly 10 NGr6[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3XRnFwOjRiaB?= NEXwVoJKSzVy78{eNlAh|ryP NELSOHIzOTd5MkC0PS=>
RIVA M2\6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q1XFI1KGh? M3jHTWlEPTExvK6yNEDPxE1? NI\3bZUzOTd5MkC0PS=>
Su-DHL2 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzoOYYzPCCq NWDRXolYUUN3MP-8olIxKM7:TR?= MkjZNlE4PzJyNEm=
Ly 1 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHW2bmQ1QCCq NX3TT2cxUUN3ME2wMlM1KM7:TR?= MXWyNVc4OjB2OR?=
Ly 7 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL4XXBGPDhiaB?= NWHWPVJkUUN3ME2wMlAzPSEQvF2= M3PVN|IyPzd{MES5
Su-DHL6 M32xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HYbVQ5KGh? MVXJR|Ux97zgMkCg{txO MX2yNVc4OjB2OR?=
Ly 10 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjROFghcA>? MnzwTWM2OD1zLkig{txO NWD2PHo2OjF5N{KwOFk>
RIVA NYLvUYppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme2OFghcA>? M2rMSWlEPTExvK6yNEDPxE1? MkH4NlE4PzJyNEm=
Su-DHL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHSOFghcA>? NHnwdVlKSzVyPUG3MlQh|ryP MVWyNVc4OjB2OR?=
Ly 1 NXHhSFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULlUXN1PzJiaB?= NEfIc41KSzVyPUCuNFEh|ryP MoHkNlE4PzJyNEm=
Ly 7 NVr0U5UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fMRVczKGh? MkPaTWM2OD1yLkCxPEDPxE1? NHTTN4EzOTd5MkC0PS=>
Su-DHL6 M{PTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDJdJNjPzJiaB?= M3rDcGlEPTB;MT62JO69VQ>? MWGyNVc4OjB2OR?=
Ly 10 M{LnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjsbXg4OiCq MX;JR|UxRTFwMjFOwG0> MnO0NlE4PzJyNEm=
RIVA M2[zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NkBp MVHJR|Ux97zgMkCg{txO NYLNdpRJOjF5N{KwOFk>
Su-DHL2 M2DqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp MVzJR|UxRTFzLkKg{txO NVH1UnlyOjF5N{KwOFk>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
water
いい結果が出るために、混じった後、直ちに使うと推めます。
10mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

Related Antibodies

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID